Question, Dr: why wasn't our CRC trial revised to add ICI's for patients with elevated PD-L1?
Aren't clinical trials frequently revised as new/pertinent information becomes known?
Why would go forward with a non-optimum trial?
(5)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-
